This study was undertaken to assess the efficacy of the herose formula as a treatment for psoriasis patients who have been previously treated with immunosuppressants. The study was an open one conducted in one center. Fifteen patients were instructed to take four herose capsules (450 mg per capsule) three times a day for 10 months. At each visit the investigator assessed each patient's PASI and therapeutic response to the treatment. The patients were treated and observed from February of 2004 to November of 2004. The results showed that the herose capsule may be an effective and safe treatment for moderate to severe plaque psoriasis.

The challenge in the second degree thermal burn wound healing is the risk of infection and Hypertrophic scarring. We administered herbal formulated HLQ ointment on second degree. Burn wound, it produced zero pain of daily dressing changes and achieved complete re epithelialization in 7-14 days.

The standard treatment of prurigo nodularis (PN) includes antihistamines, ultraviolet light, and topical and systemic corticosteroids; unfortunately, PN is notoriously resistant to the conventional therapy. Herewith is described one case of PN, which was initialized with herose as the first-line therapy resulting in complete clinical clearance. Results of follow-up examinations from 2005 to 2009 showed no evidence of recurrence. Findings indicate that herose monotherapy is a potentially promising therapeutic options for PN.

Mono- or combine immunosuppressants are commonly used for psoriasis; however the side effect caused by potent systemic immunosuppressants frequently incurred; moreover the inflammation flares up shortly after immunosuppressants are discontinued. An alternative nonimmunosuppressive therapy was introduced to psoriasis subjects. A retrospective observational study consisted of 1583 psoriasis patients who were treated with Herose Psoria capsule 1440 mg three times daily at two clinical centres, one in China, the other in Singapore, from 1 January 2000 to 1 January 2011. Psoriasis lesion evolution was photographed at monthly visit, and efficacy and safety were assessed using psoriasis area severity index PASI score grading, renal and liver function testing, and adverse event reporting and supplemented by information obtained during targeted telephone interviews. The effectiveness of Herose on psoriasis was inversely associated to prior immunosuppressants exposure (r = 0.9154), significant improvements occurred in non-immunosuppressants subjects, and complete clearance was achieved in 8 months (87.5%, 14 of 16); the wavelike evolution of psoriatic lesion appeared in prior immunosuppressants subjects.